Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS (Narrative) (Details)

v3.10.0.1
SUBSEQUENT EVENTS (Narrative) (Details) - Subsequent Event [Member]
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 30, 2018
USD ($)
$ / shares
shares
Proceeds from Issuance of Unsecured Debt $ 250
Debt, Weighted Average Interest Rate 2.00%
Loans Receivable, Net $ 500
Proceeds from services under joint venture agreement $ 1,000
Description of Controlled Equity Offering Sales Agreement In December 2018, the Company entered into a Controlled Equity Offering Sales Agreement (“Sales Agreement”) with Cantor Fitzgerald & Co.(“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock having an aggregate offering price of up to $25.0 million. The Company will pay Cantor a commission rate equal to 3.0% of the aggregate gross proceeds from each sale. The Company has not yet sold any shares pursuant to the Sales Agreement.
Budget for gene-therapy research project $ 1,500
Grants Receivable, Noncurrent 350
Security Deposit $ 1,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares 61,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares $ 13.52
Minimum [Member]  
Commitment $ 726
Maximum [Member]  
Commitment $ 962